AI biotech could be the next big platform shift

Dario Amodei thinks biotech is about to have a renaissance driven by AI.
His view is that AI could help cure a lot of diseases.
That is why some investors are looking at safer large-cap plays like LLY and higher-risk AI biotech names like ABCL and RXRX.
The bigger idea is simple: if AI can compress the timeline for drug discovery, biotech could become one of the most important markets of the next decade.